- In this issue
- » Pharma Companies get Breather
- » Law to Deter Defaulters
- » Market Update
- » And more...
Well, the 'rogue analyst' came clean yesterday. Ankit's 'jugaad' confession could make even the most value-averse heart melt.
It's not for nothing that Rahul, Richa, and I allowed Ankit into the inner sanctum of our research.
As Richa pointed out on Wednesday, Ankit is unique in the world of equity analysis. His original perspective has helped shape some of our very best recommendations over the years. Put simply: We value his input. And so do our subscribers.
But in light of his recent actions...why did we decide to allow him access to our research?
It's a good question.
At first, it seemed to us Ankit was proposing daylight robbery. And daylight robbery it is...
But then we realised Ankit is, at heart, a bit of a Robin Hood. His intention to 'leak' our ideas is noble...and having been core to our team for years, he knows what, why, and how much to share to benefit his reader.
Remember, most analysts are not generalists. That would hardly allow us to drill deep into our ideas. Most analysts I know, therefore, are experts in a specific segment (such as auto or tech) or approach to the markets (such as value investing or momentum investing).
So, while most of the research team is laser focussed on a few investing ideas - ideas that appeal to us most...ideas that we believe could create life-changing wealth for our subscribers - Ankit has the advantage of a bird's eye view.
Ankit is on a quest to be a Munger-like 'expert generalist'. That is, he's a value investor. But if you join him for lunch on any given day, you can quiz him on his latest views on bitcoins, quantum physics, evolutionary biology, neuroscience, behavioural economics, psychology... Whatever you're interested in, Ankit probably has a view. And one that could change the way you see things.
It's this expert-generalist approach that allows him to cherry pick the very best ideas with cool reserve (rather than the obsessive single-mindedness of your typical analyst).
His mantra is simple...
- Draw on that palette of diverse knowledge to recognise patterns and connect the dots across multiple disciplines.
For instance, to understand why pharma stocks are correcting, Ankit doesn't just read my macro view on pharma. He asks our chartist, Apurva, how the pharma charts are aligned. He checks with Rahul to see if his systems are throwing up any pharma bargains. Then he connects the dots.
This is not something most analysts are wired for.
So as Ankit laid out his defence recently, it became clear that his jugaad...these 'insider leaks' from across our services...offers his readers tremendous value.
Rahul, Richa, and I would rather drill deep into our research ideas than connect dots across disciplines, assets, and thought processes.
So, if Ankit's jugaad offers a way to bring it all together, we can overlook the daylight robbery.
So, is Ankit just 'stealing' our ideas. Or is there more to this insider than we know? I think it's best you hear about it from him. He has promised to share the details of his jugaad tomorrow.
02:30 Chart of the Day
By the way, there is an interesting development that will give Ankit enough fodder to gain fresh perspectives on pharma companies. In recent times, pharma companies were bogged down by mounting pressure from US Food and Drug Administration (USFDA) to adhere to quality standards at their manufacturing plants. In the past three years, the USFDA raised numerous regulatory concerns resulting in import bans and suspension of new drug approvals from facilities of Indian pharma companies. But what has come as a breather is a sharp pick-up in new drug approvals in 2017. During the period January-July 2017, 129 approvals for generic drugs were made. This is 45% higher from 89 approvals made in the corresponding period last year.
USFDA sweetener for Indian Pharma
As per the Indian Pharmaceutical Alliance, the pace of drug approvals has gained momentum after they complained to FDA about delays last year. Approvals for drugs have also picked up after USFDA concerns at some of the manufacturing units were addressed. Companies such as Divi's Laboratories, Cadila Healthcare, Sun Pharmaceuticals and Dr Reddy's Laboratories got regulatory clearances for some of their plants during the year. But several companies are still grappling to resolve FDA concerns. Some facilities of Wockhardt, IPCA and Sun Pharma are still under import alert whereas a few units of Divi's Laboratories and Dr Reddy's have received warning letters. However, FDA's move to speed up generic drug approvals in a bid to reduce healthcare costs is likely to provide some earnings relief to domestic pharma companies.
The government is leaving no stone unturned in averting future bad loan problems of banks by creating a stringent atmosphere for potential loan defaulters. After the passage of the Insolvency and Bankruptcy Law empowering RBI in stressed asset resolution, SEBI is working on a rule to make it mandatory for listed companies to disclose loan repayment defaults. This would mean that whenever a company fails to make interest and loan installment payments on time it will have to inform stock exchanges. If this SEBI rule indeed becomes a law then companies will not be able to defer their payment dues, taking advantage of the 90-day window period, only beyond which the loan gets classified as non-performing in the banks' books. In other words, this is a proactive measure that will nip the problem of willful company defaults in the bud. And will pave way for better asset quality management at banks.
Indian equity markets opened the day in red and continued to remain in the negative territory. At the time of writing, BSE Sensex was trading lower by 172 points and NSE-Nifty was lower by 34 points. Both the mid cap and small cap indices are trading up by 0.5% and 0.4%, respectively. Stocks from the healthcare and telecom sectors are witnessing maximum buying interest.
04:56 Investment Mantra of the Day
"We simply attempt to be fearful when others are greedy and greedy only when others are fearful." - Warren Buffett
|DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537.
An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes.
There are no outstanding litigations against the Company, it subsidiaries and its Directors.
GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT:
For the terms and conditions for research reports click here.
DETAILS OF ASSOCIATES:
Details of Associates are available here.
DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
DISCLOSURE WITH REGARDS TO RECEIPT OF COMPENSATION:
- 'subject company' is a company on which a buy/sell/hold view or target price is given/changed in this Research Report.
- Except for Bajaj Auto Limited and Hero MotoCorp Limited, Equitymaster has no financial interest in any other Subject Company forming a part of this report.
- Equitymaster's investment in the subject company is as per the guidelines prescribed by the Board of Directors of the Company. The investment is however made solely for building track record of its services.
- Equitymaster's Associates and Research Analyst or his/her relative doesn't have any financial interest in the subject company.
- Neither Equitymaster, it's Associates, Research Analyst or his/her relative have actual/beneficial ownership of one percent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.
- Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any other material conflict of interest at the time of publication of the research report.
- Neither Equitymaster nor it's Associates have received any compensation from the subject company in the past twelve months.
- Neither Equitymaster nor it's Associates have managed or co-managed public offering of securities for the subject company in the past twelve months.
- Neither Equitymaster nor it's Associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
- Neither Equitymaster nor it's Associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
- Neither Equitymaster nor it's Associates have received any compensation or other benefits from the subject company or third party in connection with the research report.
Definitions of Terms Used:
- The Research Analyst has not served as an officer, director or employee of the subject company.
- Equitymaster or the Research Analyst has not been engaged in market making activity for the subject company.
- Buy recommendation: This means that the subscriber could consider buying the concerned stock at current market price keeping in mind the tenure and objective of the recommendation service.
- Hold recommendation: This means that the subscriber could consider holding on to the shares of the company until further update and not buy more of the stock at current market price.
- Buy at lower price: This means that the subscriber should wait for some correction in the market price so that the stock can be bought at more attractive valuations keeping in mind the tenure and the objective of the service.
- Sell recommendation: This means that the subscriber could consider selling the stock at current market price keeping in mind the objective of the recommendation service.
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us.
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringementDisclosure & Disclaimer:
Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. The Author does not hold any shares in the company/ies discussed in this document. Equitymaster may hold shares in the company/ies discussed in this document under any of its other services.
This document is confidential and is supplied to you for information purposes only. It should not (directly or indirectly) be reproduced, further distributed to any person or published, in whole or in part, for any purpose whatsoever, without the consent of Equitymaster.
This document is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity, who is a citizen or resident or located in any locality, state, country or other jurisdiction, where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject Equitymaster or its affiliates to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, Canada or the European Union countries, the same may be ignored.
This document does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Our research recommendations are general in nature and available electronically to all kind of subscribers irrespective of subscribers' investment objectives and financial situation/risk profile. Before acting on any recommendation in this document, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the securities referred to in this material and the income from them may go down as well as up, and subscribers may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. Information herein is believed to be reliable but Equitymaster and its affiliates do not warrant its completeness or accuracy. The views/opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time without notice. This document should not be construed as an offer to sell or solicitation of an offer to buy any security or asset in any jurisdiction. Equitymaster and its affiliates, its directors, analyst and employees will not be responsible for any loss or liability incurred to any person as a consequence of his or any other person on his behalf taking any decisions based on this document.
As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use
, available here. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407